Literature DB >> 7194078

Hemodynamic effects of the new vasodilator drug Bay k 5552 in man.

A Vogt, K L Neuhaus, H Kreuzer.   

Abstract

The hemodynamic effects of the new vasodilator drug isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinecarboxylate (nisoldipine, Bay k 5552) were observed in 9 patients undergoing cardiac catheterization. The drug was administered i.v. in a dose of 1.5 microgram/kg body weight. Within 1 min after injection aortic pressure decreased by 11.5 +/- 6.4%, cardiac index increased by 23.1 +/- 13.5%, and heart rate accelerated by 18.3 +/- 10.1% of control value. Calculated total peripheral resistance was reduced by 28.2 +/- 10.1%. The whole low pressure system as well as the dp/dt max remained unaffected by the drug. The stroke volume index showed a slight and insignificant increase. Thus, Bay k 5552 represents a fast and power fully acting vasodilating substance with its actions being restricted mainly to the peripheral vasculature.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7194078

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  9 in total

Review 1.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 2.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

3.  Haemodynamic and radionuclide effects of amlodipine in coronary artery disease.

Authors:  B Silke; S P Verma; A V Zezulka; S Sharma; G Reynolds; N C Jackson; S Guy; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

4.  An exercise hemodynamic comparison of verapamil, diltiazem, and amlodipine in coronary artery disease.

Authors:  B Silke; E Goldhammer; S K Sharma; S P Verma; S H Taylor
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

5.  Nisoldipine tablets once daily versus nifedipine capsules three times daily in patients with stable effort angina pectoris pretreated with atenolol.

Authors:  T R Pedersen; M Kantor
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

Review 6.  The pharmacology of nisoldipine.

Authors:  A Knorr
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

7.  Nisoldipine: kinetics and effects on blood pressure and heart rate in patients with liver cirrhosis after intravenous and oral administration.

Authors:  J van Harten; P van Brummelen; J H Wilson; M T Lodewijks; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Energy conservation by nisoldipine in ischaemic heart.

Authors:  J W De Jong; T Huizer; J G Tijssen
Journal:  Br J Pharmacol       Date:  1984-12       Impact factor: 8.739

9.  The effects of nisoldipine (Bay K 5552) on cardiovascular performance and regional blood flow in pentobarbital-anaesthetized pigs with or without beta-adrenoceptor blockade.

Authors:  D J Duncker; J M Hartog; P G Hugenholtz; P R Saxena; P D Verdouw
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.